Features

Bill Bennett, MD, FASN

/kidneynews/8_7/12/graphic/12f1.jpg

William Couser, MD

The recent finding that the experimental drug CMX-2043—developed to prevent ischemic-reperfusion injury (IRI)—does not reduce the risk of contrast-induced kidney injury compared to placebo dealt a setback to the search for agents to prevent the condition. The negative clinical trial results were presented at the American College of Cardiology (ACC) meeting, held this spring in Chicago.

The American Board of Internal Medicine (ABIM) recently announced plans to begin offering physicians new Maintenance of Certification (MOC) options. The proposed changes come after months of pushback by the medical community and still may not go far enough in addressing concerns.

On June 1, 2016, three major nephrology societies signed a declaration of collaboration.

Nephrologists have always been considered among the best educators in medicine. Our commitment to excellence in patient care and research extends to finding innovative ways to teach students, residents, and fellows about some of the most complex (and interesting) issues physicians and scientists face.

Pages